220 related articles for article (PubMed ID: 28614908)
1. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
Santos JM; Havunen R; Siurala M; Cervera-Carrascon V; Tähtinen S; Sorsa S; Anttila M; Karell P; Kanerva A; Hemminki A
Int J Cancer; 2017 Oct; 141(7):1458-1468. PubMed ID: 28614908
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Siurala M; Havunen R; Saha D; Lumen D; Airaksinen AJ; Tähtinen S; Cervera-Carrascon V; Bramante S; Parviainen S; Vähä-Koskela M; Kanerva A; Hemminki A
Mol Ther; 2016 Aug; 24(8):1435-43. PubMed ID: 27357626
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
Santos JM; Cervera-Carrascon V; Havunen R; Zafar S; Siurala M; Sorsa S; Anttila M; Kanerva A; Hemminki A
Mol Ther; 2018 Sep; 26(9):2243-2254. PubMed ID: 30017877
[TBL] [Abstract][Full Text] [Related]
4. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
5. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
[TBL] [Abstract][Full Text] [Related]
7. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Kerkar SP; Muranski P; Kaiser A; Boni A; Sanchez-Perez L; Yu Z; Palmer DC; Reger RN; Borman ZA; Zhang L; Morgan RA; Gattinoni L; Rosenberg SA; Trinchieri G; Restifo NP
Cancer Res; 2010 Sep; 70(17):6725-34. PubMed ID: 20647327
[TBL] [Abstract][Full Text] [Related]
9. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.
Zatloukal K; Schneeberger A; Berger M; Schmidt W; Koszik F; Kutil R; Cotten M; Wagner E; Buschle M; Maass G
J Immunol; 1995 Apr; 154(7):3406-19. PubMed ID: 7897222
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.
Garcia-Hernandez Mde L; Hamada H; Reome JB; Misra SK; Tighe MP; Dutton RW
J Immunol; 2010 Apr; 184(8):4215-27. PubMed ID: 20237297
[TBL] [Abstract][Full Text] [Related]
11. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
12. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.
Cui NP; Xie SJ; Han JS; Ma ZF; Chen BP; Cai JH
Chin Med J (Engl); 2012 Mar; 125(5):794-800. PubMed ID: 22490577
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
14. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
15. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
17. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8
Etxeberria I; Bolaños E; Quetglas JI; Gros A; Villanueva A; Palomero J; Sánchez-Paulete AR; Piulats JM; Matias-Guiu X; Olivera I; Ochoa MC; Labiano S; Garasa S; Rodriguez I; Vidal A; Mancheño U; Hervás-Stubbs S; Azpilikueta A; Otano I; Aznar MA; Sanmamed MF; Inogés S; Berraondo P; Teijeira Á; Melero I
Cancer Cell; 2019 Dec; 36(6):613-629.e7. PubMed ID: 31761658
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2.
Nakamura Y; Wakimoto H; Abe J; Kanegae Y; Saito I; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1994 Nov; 54(22):5757-60. PubMed ID: 7525049
[TBL] [Abstract][Full Text] [Related]
19. [Infusion of ex vivo expanded homologous CD4⁺;CD25⁺; regulatory T cells promotes the susceptibility to tumor in mice].
Guo T; Luo S; Xu J; Dai J; Liu Z; Gao X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 May; 30(5):466-70. PubMed ID: 24796739
[TBL] [Abstract][Full Text] [Related]
20. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]